Introduction
The typical thickness of the retina in people with healthy eyes is 200 lm, which can vary slightly according to the part of the retina measured and type of ocular coherence tomography (OCT) used, with separate studies having reported either no change or a small decrease in thickness with increasing age 1,2 . Damage to the eye caused by conditions such as macular edema or trauma can lead to abnormal fluid accumulation, resulting in thickening of the retina. Along with other microvascular changes, thickening of the retina follows sustained periods of hyperglycemia in people with diabetes. Although macular edema does not always result in a deterioration in vision, disruption of the fovea can cause severe visual impairment 1 .
The fluocinolone acetonide (FAc) 190 mg intravitreal implant was evaluated in the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) study program 3, 4 . Continuous daily release of low levels of FAc from the implant has been found to result in a reduction in foveal thickness and edema for up to 3 years 4 .
Historically, laser photocoagulation was considered to be the treatment of choice for DME, due to favorable results from the Early Treatment Diabetic Retinopathy Study (ETDRS) 5 . The FAME study, therefore, evaluated FAc intravitreal implant in people with an inadequate response to retinal laser therapy. However, since the FAME study was conducted, several landmark trials have demonstrated that anti-vascular endothelial growth factor (anti-VEGF) therapy can lead to a significant improvement in vision in people with DME [6] [7] [8] [9] , and anti-VEGF therapy is now generally considered to be the first-line therapy for this condition. Therefore, in Europe, FAc intravitreal implant is presently indicated for the management of chronic DME only where an insufficient response has been achieved with first-line anti-VEGF therapy. The aim of the ILUVIEN Clinical Evidence Study in the UK (ICE-UK) was to assess the effectiveness of FAc intravitreal implant for DME in real world clinical practice. The purpose of this study was specifically to evaluate retinal thickness 12 months before and after treatment with the FAc 190 mg intravitreal implant.
Methods

Data source
The dataset and study methodology have been described in detail elsewhere 10 . Briefly, for this retrospective, multi-center,hospital-based study, data were extracted from medical records for a representative cohort of people treated at 13 participating hospitals in the UK and combined into a single dataset for the purpose of analysis. Data were generated from retrospective case reviews, pseudonymized, and entered into an online data entry tool. The following data were collected at several time points within a pre-specified period: patient demographics, medical history, implant data, and data from multi-disciplinary and medication reviews.
Ethical approval
The lead clinician and Caldicott Guardian at each center gave written approval for extraction of anonymized data. The study protocol was approved by the head of research governance at the lead clinical center. This study was conducted in accordance with the Declaration of Helsinki and the UK Data Protection Act.
Subjects
Subjects were people with type 1 or type 2 diabetes treated with FAc 190 mg intravitreal implant for DME in at least one eye at a participating site as part of their routine care between April 1, 2013 and April 15, 2015. A requirement was a minimum of 12 months' history prior to implant. Those with a history of taking part in any other interventional study for DME or who were lost to follow-up were excluded. The index date was defined as the date of first recorded FAc intravitreal implant into the study eye. The follow-up period was defined as 12 months post-implant and subjects who received FAc intravitreal implant in both eyes were allowed to contribute both eyes to the study.
Outcomes
The following clinical outcomes were investigated at 3, 6, and 12 months post-index date: changes in central foveal thickness (CFT) and central subfield thickness (CST) and the proportion of treated eyes that demonstrated a 10%, 25%, and 50% improvement in CFT or CST. The distribution of CFT and CST from 12 months prior to and 12 months postimplant was also investigated. Due to the observational nature of this study, there was no restriction on the OCT machine type used to measure retinal thickness.
Subgroups
Results are presented overall and for two subgroups, based on higher and lower CFT at implant (400 mm and <400 mm, respectively). Eyes with no recorded CFT measurement at baseline were excluded from the subgroup analyses.
Statistical analysis
Changes in retinal thickness were compared between implant and the 3-, 6-, and 12-month time points using the non-parametric Wilcoxon signed ranks test. The proportion of people achieving a reduction in retinal thickness between implant at these time points was compared between subgroups using Fisher's exact test. The proportion of people achieving a target retinal thickness was compared between implant and the 3-, 6-, and 12-month time points using McNemar's test. Last observation carried forward was implemented to impute missing values in two stages: on or before index date and after index date 11 .
Mean and median CFT and CST were calculated on a daily basis for the 12 months before and after FAc implant. In order to smooth the data, missing values for each day of this 24-month period were imputed using linear interpolation 11 . As linear interpolation could not be used before the first recorded value or after the last recorded value, nearest observation carried forward and backwards was used to impute the remaining missing values. In order to investigate whether CFTs <200 mm have a detrimental effect on vision, visual acuity (ETDRS letter score) in the 12 months prior to and post FAc implant was investigated for study eyes with a CFT of <200 mm at baseline using the same methodology.
The strength and direction of the association between pairs of visual acuity and CFT measurements recorded at FAc implant, 12 months post-FAc implant and at any time in the 12 months prior to and post-FAc implantation were measured using the Pearson's correlation coefficient. Statistical analyses were carried out using IBM SPSS Statistics version 20.
Results
Data were collected on 311 people, of whom 208 people contributing data from 233 eyes treated with FAc intravitreal implant (study eyes) were eligible for inclusion in the study cohort. An attrition flow diagram has been previously presented 10 . Of the 233 study eyes, 208 were first eyes treated with the implant, and 25 were a second treatment in the subject's other eye.
Patient demographics
Of the 208 people treated with FAc intravitreal implant in any eye, 128 (62%) were male. The mean age was 68.1 years; 176 (85%) had type 2 diabetes (Table 1) . Median (interquartile range, IQR) duration of diabetes was 18 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) years. Sixty-three eyes (27%) had a CFT of <400 mm at the time of implant, and 128 (55%) eyes had a CFT of 400 mm at the time of implant. Forty-two study eyes had no recorded CFT measurement within the 12-month period prior to implant, and were, therefore, excluded from the subgroup analysis. 
CFT, central foveal thickness; SD, standard deviation; IQR, interquartile range; LogMAR, Logarithm of the Minimum Angle of Resolution; ETDRS, Early Treatment Diabetic Retinopathy Study; CST, central subfield thickness; IOP, intraocular pressure; VEGF, vascular endothelial growth factor. a These are estimates, as it was not possible to determine the exact date on which these parameters were recorded in the dataset.
b
Include operations carried out on day of implant (n ¼ 18).
Although some of the characteristics relate to the individual and not the eye, each eye was analyzed as an independent observation. Table 2 .
Change in central foveal thickness.
CFT, central foveal thickness; IQR, interquartile range.
Central foveal thickness
Not all subjects had relevant observations at all time points. Following multiple imputation of missing values and reporting only paired observations, the median (IQR) CFT decreased following Table 2 ).
A reduction of 10% in CFT from implant was observed in 76 (51%), 96 (57%), and 113 (65%) treated eyes at 3 months, 6 months, and 12 months post-implant, respectively. A reduction of 25% and 50% in CFT from implant was observed in 61 (41%) and 21 (14%) treated eyes at 3 months, 75 (44%) and 30 (18%) at 6 months, and 87 (50%) and 37 (21%) at 12 months, respectively. When compared with eyes with a CFT of <400 mm at the time of implant, eyes with a CFT of 400 mm at implant were significantly more likely to achieve a reduction in CFT of 25% and 50% at 3 months (p < .001, p < 0.001, and p ¼ .004, respectively), 6 months (all p < .001), and 12 months (all p < .001).
Mean CFT was higher in the 12 months prior to implant compared with the 12 months after implant, and tended to increase in the 3 months immediately prior to implant (Figure 1(a) ). CFT continued to gradually decrease throughout the 12 months following implant.
When compared with baseline, a steeper cumulative frequency curve was observed at 12 months follow-up, with more study eyes achieving lower CFTs at 12 months following FAc implant ( Figure  2) . However, the proportion of study eyes with a CFT of 150 mm was the same prior to and 12 months post-FAc implant (2%). The distribution of study eyes by CFT category of <200 mm, 200 and <300 mm, 300 and <400 mm, and 400 mm at FAc implant and 12 months postFAc implant is described in Figures 3(a and b) . Most study eyes had a CFT of 400 mm at the time of FAc implantation (66%). At 12 months post-FAc implant, 51% of study eyes moved to a lower CFT category, 7% moved to a higher CFT category, and 42% remained in the same category. CFT was <300 mm in 16% of eyes at implant and 47% of eyes at 12 months post-implant (p < .001, Figure  2 ). For eyes with a CFT <400 mm at the time of implant, CFT was <300 mm in 47% of eyes at the time of FAc implant and 66% of eyes at 12 months (p ¼ .382). In those eyes with a CFT of 400 mm at the time of FAc implant, 38% achieved a CFT of <300 mm at 12 months post-implant. Following FAc implant, 6% of eyes had a CFT of <200 mm at the time of FAc implant and 19% of eyes had a CFT of <200 mm at 12 months (p < .001). Changes in visual acuity in the 12 months prior to and postFAc implant are detailed in Figure 4 for these study eyes. For study eyes with a CFT of <200 mm at FAc implant, visual acuity was slightly higher in the 12 months post-FAc implant than in the 12 months prior to FAc implant. Comparing the 12 months prior to and postFAc implant, a larger improvement in visual acuity was observed in study eyes with a CFT of >200 mm at FAc implant and a CFT of <200 mm at 12 months post-FAc implant.
At FAc implantation, a Heidelberg SPECTRALIS OCT machine was used to measure retinal thickness in 61% of eyes with a recorded CFT; Topcon 3D OCT-2000 was used in 38% of eyes; and Topcon 3D OCT-1000 was used in 1% of eyes. The corresponding values were 56%, 41%, and 3%, respectively, at 3 months; 58%, 38%, and 3%, respectively, at 6 months; and 59%, 38%, and 3%, respectively, at 12 months. Retinal thickness was measured using different OCT machine types at baseline and at 3, 6, and 12 months post-FAc implant in 5%, 7%, and 7% of eyes, respectively. In study eyes whose CFT was measured using a Heidelberg SPECTRALIS machine both prior to FAc implant and 12 months following implant, median CFT decreased from 492 mm (IQR ¼ 388-647 mm) to 302 mm (210-421 mm, n ¼ 99). In study eyes where a Topcon 3D OCT-2000 was used both at baseline and 12 months follow-up, median CFT decreased from 413 mm (IQR ¼ 323-514 mm) to 317 mm (293-436 mm, n ¼ 62).
Correlation between central foveal thickness and visual acuity
There was a statistically significant negative correlation between visual acuity (ETDRS letter score) and CFT at FAc Table 3 ).
A reduction of 10% in CST was observed in 83 (54%), 103 (58%), and 118 (65%) treated eyes at 3 months, 6 months, and 12 months post-implant. A reduction of 25% and 50% in CFT from implant was observed in 47 (30%) and 13 (8%) treated eyes at 3 months, 62 (35%) and 23 (13%) at 6 months, and 76 (42%) and 25 (14%) at 12 months, respectively.
Following linear interpolation of missing values (with nearest observation carried forward and backwards to impute missing values before the first recorded measurement and after the last recorded measurement), mean CST was higher in the 12 months prior to implant than in the 12 months post-implant (Figure 1(b) ). An increase in mean CST was observed in the 4 months prior to implant. CST continued to decrease gradually throughout the 12-month period following implant.
Discussion
In the 12 months prior to the insertion of the FAc intravitreal implant, central retinal thickness continued to increase. Following implant, there was a marked reduction in the central retinal thickness. The onset of the beneficial changes in the morphology of the retina appeared to be both rapid and sustained for the period of this study. Response was based on CFT prior to treatment with the FAc intravitreal implant, being greater in those with a higher CFT (400 mm) at baseline and less in those eyes with a lower CFT (<400 mm) at baseline. Several types of OCT machine types were used to measure retinal thicknesses across the 13 participating ophthalmology centers. Retinal thickness measurements have been shown to vary depending on machine type, which is thought to be due to variation in the retinal segmentation algorithms 12 . The same OCT machine in each unit was used to measure retinal thickness at baseline, and the three follow-up time points in most study eyes.
Whilst bearing in mind that retinal thinning due to cell loss can also be harmful 13 , in the longer term, it has been reported that eyes that improve most in visual acuity have the greatest decrease in retinal thickness 14 . Nevertheless, the association between visual acuity and retinal thickness is still poorly understood 15, 16 . In this study, a significant negative association between visual acuity (ETDRS letter score) and CFT was observed. However, the variation in visual acuity explained by CFT was low. The Diabetic Retinopathy Clinical Research Network has previously investigated the relationship between retinal thickness and visual acuity before and after laser treatment in patients with DME, and a moderate correlation between visual acuity and center point thickness was observed (correlation coefficient of 0.52 at baseline and 0.49, 0.36, and 0.38 at 3.5, 8, and 12 months post-laser photocoagulation). Furthermore, a correlation between change in visual acuity and change in center point thickness was also reported (correlation coefficient of 0.44, 0.30, and 0.43 at 3.5, 8, and 12 months post-laser photocoagulation) 17 . However, the researchers also observed considerable variation in visual acuity for a particular level of retinal edema 17 .
What is not a matter of conjecture is that any increase in retinal thickness from the norm represents physiological morbidity. Cataract surgery increases retinal thickness 18 , and recovery in retinal thickness varies by the region of the retina 19 . However, central point thickness has been shown to recover relatively quickly following cataract surgery in people pre-treated with the FAc intravitreal implant 20 . Panretinal photocoagulation is reported to increase local inflammation, resulting in effects such as localized cytokine release 21 . In the later stages of diabetic eye diseases, multiple treatments are typically used together in complex patterns of treatment to salvage sight. Retinal thickness is thought to be an important and objective measure of clinical outcome 14 .
Anti-VEGF therapy is now considered to be the first-line treatment for DME, and this class of drugs has been shown to be effective in reducing retinal thickness 6, [22] [23] [24] [25] [26] [27] . The two licensed anti-VEGF products for DME available in the UK-ranibizumab and aflibercept-have been recommended by NICE for the treatment of DME in eyes with a central retinal thickness 400 mm, since both products have been determined to be cost-effective only in those eyes with this central retinal thickness 28, 29 . However, the NICE recommendation for FAc intravitreal implant does not include any restrictions based on central retinal thickness 30 . Laser therapy or intravitreal steroids (in eyes with a pseudophakic lens) are the only recommended treatment options in eyes with a central macular thickness of <400 mm. In this study, we examined changes in CST and CFT in subgroups based on baseline CFT of <400 mm and 400 mm. The change in CFT between implant and the end of the 12-month observation period was statistically significantly greater in those with a CFT of 400 mm at the time of implant, but not in those eyes with a CFT of <400 mm. Eyes with a smaller CFT at the time of FAc implant have less potential to improve. Sample size was relatively small in the CFT subgroups.
A reduction in retinal thickness post-FAc implant has also been observed in other studies. In the FAME study, baseline mean foveal thickness was 451 mm and 461 mm in the sham and low dose (0.2 mg/day) groups, respectively 4 . At 6 months, the mean foveal thickness was 396 mm in the sham group and 318 mm in the 0.2 mg/day group 4 . At 36 months, mean foveal thickness was 309 m and 280 mm, respectively 4 . Similar results were observed in this study, where median CFT in study eyes had decreased from 464 mm at implant to 331 mm at 6 months. By 12 months, median CFT was 309 mm. In the largest published observational study to date, ElGhrably et al. 31 reported a mean reduction in central macular thickness of 126 lm at 12 months following FAc implant. In line with the findings from this study, central macular thickness decreased rapidly after implant, and this was sustained for the 12-month follow-up period 31 . Several other smaller observational studies have investigated the change in central retinal thickness following FAc intravitreal implant for DME. In a retrospective study conducted by Elaraoud et al. 32 , central retinal thickness was found to have decreased by a mean of 149 mm at 3 months post-FAc implant. In this study, 7% of study eyes moved into a higher CFT category between baseline and 12 months post-FAc implant. Elaraoud et al. 32 also reported a worsening in CFT in four out of the 22 eyes included in their retrospective study at 3 months postimplant. In a prospective, non-randomized, phase 4, pilot study, Figueira et al. 33 observed a statistically significant decrease in CST 12 months after FAc implant, and a rapid decrease in CST in the first week after implant. Rapid and sustained reductions in CST following FAc implant were also observed in a prospective study conducted by Massin et al. 34 
Strengths and limitations
The strengths and limitations of the study have been described previously 10 . As this is an observational study, several limitations are likely to apply, including the misclassification of outcomes, effectiveness, and safety. Outcomes were not measured at set times post-index, and were not consistently available across all participating centers for all the time points. Recall of participants to attend measurement may have led to differential misclassification and missing values. There were inconsistencies in the information recorded on cataract operations and lens status. Duration of DME was not recorded. Analysis was restricted to 12 months follow-up postimplant, because available follow-up after this date varied from person to person. First and second treated eyes from the same person were analyzed as independent observations. However, second eyes may be more likely to be treated with FAc intravitreal implant if the patient had a positive response to treatment in the first eye. In addition, treatment of the second eye may be more likely to occur at certain treatment centers. Whilst minimizing the elimination of individuals from the analysis, methods used to impute missing values have inherent limitations. The last observation carried forward can produce a biased estimate of treatment effect. However, as retinal thickness continued to improve over the duration of the period of follow-up, we believe that last observation carried forward will provide a conservative estimate for the effect of FAc on retinal thickness.
Conclusions
In our cohort of people with DME, where 96% had a prior history of receiving anti-VEGF injections, laser therapy, and/or other intravitreal steroids, central retinal thickness increased in the 12 months prior to the insertion of the FAc intravitreal implant. Following treatment with the FAc intravitreal implant, a marked and sustained reduction in central foveal thickness was observed in the 12 months following implant. A statistically significant negative correlation between central foveal thickness and visual acuity (ETDRS letters score) was also observed. However, the variance in visual acuity accounted for by central foveal thickness was low.
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